fashion -WSS

fashion

author：Wikipedia 2025-09-29 22:47:10 - browse：266

A dosage of Wegovy, a drug used for weight loss — Amanda Andrade-Rhoades/AP

U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment.

The new label indicates that Wegovy can be used to reduce the risk of major heart complications — including heart attack, stroke, or cardiovascular-related deaths — for people with overweight or obesity and existing heart disease, Novo said in a statement Friday.

The decision was based on results of a large, five-year trial that showed Wegovy cut the risk of cardiovascular problems by 20% in that population. This is the first time a weight loss treatment has been approved to also help improve heart outcomes, the FDA said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

WSS

Congress might make insulin pumps more accessible to the blind

He's a Nobel laureate. Critics say he was misleading on Covid

PBM reform efforts get punted in Congress

Alabama hospital puts IVF treatments on hold

A new nitrogen execution bill also undermines medical licensing

PBM reform efforts get punted in Congress

focus

fashion

Wikipedia

Apple is now the first public company to be valued at $3 trillion

NIH study of ME/CFS points to clear biological hallmarks

Moonlake's readout produced a cash windfall. Risks remain

STAT Boddities: What happens to the brain when we get scared?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Long Covid research funding gets a major boost from NIH

Peter Hotez and the public health issue of online harassment

A solution to the after

How to save PrEP access — and even expand it

Websites selling Wegovy, Zepbound ingredients targeted by FDA

knowledge

Medicare inequities exacerbate Puerto Rico’s health disparities

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Juul documents reveal insider tactics on political lobbying

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Tome Biosciences co

Artificial intelligence use in health care faces greater scrutiny in 2024

hotspot

focus

hotspot

hotspot